American Century Companies Inc. Cuts Holdings in Supernus Pharmaceuticals, Inc. $SUPN

American Century Companies Inc. lowered its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 19.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 916,154 shares of the specialty pharmaceutical company’s stock after selling 219,158 shares during the quarter. American Century Companies Inc.’s holdings in Supernus Pharmaceuticals were worth $28,877,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new position in Supernus Pharmaceuticals in the first quarter worth $41,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Supernus Pharmaceuticals during the first quarter worth about $46,000. GAMMA Investing LLC lifted its stake in Supernus Pharmaceuticals by 116.7% during the second quarter. GAMMA Investing LLC now owns 2,861 shares of the specialty pharmaceutical company’s stock worth $90,000 after purchasing an additional 1,541 shares during the last quarter. CWM LLC boosted its holdings in shares of Supernus Pharmaceuticals by 92.4% in the 2nd quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 1,479 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Supernus Pharmaceuticals during the 1st quarter valued at about $103,000.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $45.66 on Monday. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $57.65. The company’s 50 day moving average price is $48.59 and its 200-day moving average price is $40.99. The stock has a market capitalization of $2.62 billion, a price-to-earnings ratio of 39.70 and a beta of 0.75.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.36). The firm had revenue of $170.00 million for the quarter, compared to analysts’ expectations of $175.82 million. Supernus Pharmaceuticals had a net margin of 9.70% and a return on equity of 14.22%. The company’s quarterly revenue was up 9.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.69 EPS. Supernus Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current fiscal year.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 59,900 shares of the company’s stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $50.57, for a total transaction of $3,029,143.00. Following the completion of the transaction, the chief executive officer owned 1,206,578 shares of the company’s stock, valued at $61,016,649.46. This represents a 4.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Frank Mottola sold 5,000 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $45.87, for a total value of $229,350.00. Following the completion of the sale, the senior vice president owned 15,496 shares of the company’s stock, valued at approximately $710,801.52. This trade represents a 24.40% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 183,135 shares of company stock valued at $8,773,587. 8.80% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. TD Cowen boosted their target price on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Bank of America assumed coverage on shares of Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They set a “buy” rating and a $65.00 price target on the stock. Cantor Fitzgerald boosted their price objective on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a report on Tuesday, September 30th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Piper Sandler upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $40.00 to $65.00 in a research report on Thursday, October 9th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Supernus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $63.25.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.